Several NLRs have been implicated in the production of IFNs and inflammatory cytokines during SARS-CoV-2 infection. For instance, silencing of an intracellular sensor of bacterial peptidoglycans, nucleotide-binding oligomerization domain-containing protein 1 (NOD1; also known as NLRC1), in Calu-3 cells during SARS-CoV-2 infection reduces the expression of IFN-β [
47]. NLRC1 may mediate SARS-CoV-2 infection-induced NF-κΒ activation or directly bind viral RNA and regulate the MDA5-MAVS complex formation to modulate IFN-β production [
55]. Several reports have demonstrated that NLRP3 is also involved in coronavirus infections (Fig.
1C). NLRP3 is a canonical inflammasome sensor, and it forms a multiprotein complex with the adaptor apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) and caspase-1 in response to PAMP/DAMP sensing. Inflammasome formation results in the activation of caspase-1 to cleave its substrates, including the pro-inflammatory cytokines IL-1β and IL-18 to produce their bioactive forms. Caspase-1 also cleaves gasdermin D (GSDMD) to release its N terminal fragment to form pores in the membrane and induce cell death, pyroptosis [
56]. The SARS-CoV-2 N protein is thought to bind to GSDMD to inhibit pyroptosis [
57]. However, other studies have suggested that NLRP3 inflammasome activation and pyroptosis still occur during SARS-CoV-2 infections. NLRP3 deficiency inhibits caspase-1 and GSDMD activation in a murine coronavirus infection model with mouse hepatitis virus (MHV) [
58], indicating that coronaviruses induce NLRP3 inflammasome assembly. Additionally, microscopy of monocytes and lung tissue samples from patients with COVID-19 show the formation of NLRP3 and ASC puncta, suggesting the formation of NLRP3 inflammasomes in these patients [
59]. Moreover, SARS-CoV-2–infected human primary monocytes show NLRP3-dependent caspase-1 cleavage, GSDMD cleavage, and IL-1β maturation [
59,
60]. NLRP3 is upregulated and activated by multiple SARS-CoV-2 PAMPs, including GU-rich RNAs, E, N, and open reading frame (ORF) 3a proteins [
18,
61‐
63]. In response to the SARS-CoV-2 S protein, NLRP3 expression and IL-1β release are upregulated in macrophages from patients with COVID-19 but not in macrophages from healthy patients [
64]. Additionally, SARS-CoV-2 N protein interacts directly with NLRP3, thereby facilitating the binding of NLRP3 with ASC [
62]. N protein-mediated lung injury, inflammation, and death in mice is reduced upon treatment with an NLRP3 inflammasome inhibitor, MCC950, or a caspase-1 inhibitor, Ac-YVAD-cmk [
62]. MCC950 treatment also alleviates excessive lung inflammation and COVID-19–like pathology in adeno-associated virus (AAV)-hACE2 transgenic mice, indicating that the NLRP3 inflammasome induces excessive inflammatory responses during SARS-CoV-2 infection [
65]. This detrimental effect of NLRP3 during SARS-CoV-2 infection is further supported by the finding that the severe pathology induced by SARS-CoV-2 in lung tissues is reduced in
Nlrp3–/– mice compared to wildtype mice [
65]. Activation of the NLRP3 inflammasome is also seen in peripheral blood mononuclear cells (PBMCs) and tissues of postmortem patients with COVID-19 upon autopsy [
59]. Moreover, higher levels of inflammasome-dependent products, such as IL-18 and active caspase-1, are associated with disease severity and poor clinical outcome [
59]. Collectively, these data suggest that SARS-CoV-2 activates the NLRP3 inflammasome. Additionally, during SARS-CoV-2 infection, the expression of proteins involved in non-canonical NLRP3 inflammasome signaling, through caspase-11 and caspase-4, are upregulated in the lungs of mice and humans, respectively. Deficiency of caspase-11, but not GSDMD, an executioner of pyroptosis, reduces disease severity in SARS-CoV-2–infected mice [
66], suggesting that caspase-11 (or caspase-4/5 in humans) may promote disease severity in COVID-19 independently of pyroptosis. Caspase-4/11 can be activated by oxidized phospholipids that are produced in damaged tissues (Fig.
1D) [
67]. Thus, it is possible that this activation occurs during SARS-CoV-2 infection. Oxidized phospholipids are reportedly upregulated in patients with COVID-19 [
68,
69], and outside the context of COVID-19, they induce cytokine release in a caspase-4/11–dependent manner without requiring GSDMD-dependent cell death [
67].